February 18, 2022

Relatlimab and nivolumab in untreated and metastatic melanom

In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase 2-3 study evaluated the combination of relatlimab (anti LAG-3) and nivolumab […]
February 18, 2022

Zuma-5: long-term follow-up demonstrates substantial and sustained benefit of axicabtagene ciloleucel (axi-cel) for iNHL

Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy indicated for the treatment of Relapsed/Refractory (R/R) large B-cell lymphoma and follicular lymphoma (FL), both after […]
February 18, 2022

Prognosis impact of early adjuvant treatment discontinuation in stage III C

A pooled ACCENT/IDEA analysis demonstrates that for patients with stage III colorectal cancer treated with 6 months of oxaliplatin-based adjuvant chemotherapy, discontinuation of oxaliplatin while maintaining […]
February 18, 2022

New dimensions of cancer hallmarks

Cancer hallmarks are a tool for understanding the vast complexity of cancer phenotypes and genotypes. As knowledge of cancer mechanisms has progressed, other facets of the […]
February 18, 2022

KEYNOTE – 394: Pembrolizumab in second-line treatment of advanced HCC

The phase 3 study, KEYNOTE-394, demonstrated significant benefit of using pembrolizumab in combination with best supportive care for Asian patients with advanced hepatocellular carcinoma (HCC) in […]
February 18, 2022

Checkmate 9X8 addition the nivolumab in regimen the first -line treatment of metastatic colorectal cancer

Although the primary endpoint of this phase 2 study was not met, the addition of nivolumab to the standard first-line treatment for metastatic colorectal cancer showed […]
February 18, 2022

Cemiplimab shows survival benefit in patients with cervical cancer

Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared with chemotherapy of investigator’s choice, for patients with recurrent or metastatic […]
July 12, 2021

GeparNUEVO: durvalumab plus neoadjuvant chemotherapy in TNBC demonstrates long-term clinical benefit

There was a small increase in pCR initially (with no continuity after surgery), questioning the need to maintain immunotherapy as adjuvant treatment, according to data presented in ASCO 2021  During ASCO World Congress […]
July 7, 2021

CheckMate 648: first-line immunotherapy as a new standard of care for advanced esophageal SCC

Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]